Quarterly Earnings

IDEXX prepares to release its 2025 results, with all eyes on whether its high-tech product launches can sustain momentum in a complex pet care market.

Beyond a simple time change, Fortrea's upcoming JPM presentation is a critical test for its new CEO and a key moment to define its future in the CRO market.

As Encompass Health sets its Q4 earnings date, investors watch to see if the rehab giant can sustain its impressive 2025 growth amid industry pressures.

With record revenue and a bold AI strategy, Opera heads to a key investor conference. Can its 'agentic' browsers redefine the web and win market share?

Upbound Group's new CEO and CFO head to the prestigious ICR Conference. Investors await insights on growth, credit trends, and financial inclusion strategy.

Ocugen heads to a top investor conference with a bold plan for its gene-agnostic therapy, aiming to treat blindness and secure its future in a crowded market.

With blockbuster preliminary sales and rapid patient adoption, Liquidia's new inhaled therapy is challenging established players in the lung disease space.

Pandora's 2025 growth slows amid weak consumer sentiment, but a new CEO plans a strategic reset to combat rising costs and boost brand desirability.

Sanuwave Health posts record revenue, defying industry-wide turmoil as reimbursement cuts reshape the advanced wound care market. How did they do it?

With a 12% increase in gold reserves, Aris Mining's Segovia mine proves its mettle as a world-class asset, fueling an aggressive expansion in South America.

Operational failures at a key Texas plant and a sudden drop in chlorine demand force chemical giant Olin Corp. to drastically cut its Q4 earnings forecast.

Collegium Pharmaceutical projects robust 2026 revenue fueled by its ADHD drug Jornay PM, savvy debt refinancing, and a proactive generic strategy.

The opioid treatment specialist projects over $1.1B in revenue, driven by its flagship drug SUBLOCADE and a major strategic overhaul in the U.S.

Amid market headwinds, JD.com cancels $3B in shares to boost value, signaling deep confidence while juggling costly strategic growth initiatives.

Sana Biotechnology prepares for its pivotal J.P. Morgan update, balancing groundbreaking diabetes data against a ticking financial clock and fierce competition.

Asure Software appoints veteran COO Mike Eralie to scale operations, signaling a strategic push to enhance client experience in the competitive HCM market.

As legacy brand Hamilton Beach heads to a major conference, its high-stakes pivot from kitchen gadgets to health tech will be under the microscope.

With a major acquisition and a volatile stock, all eyes are on ServiceNow's Jan 28 results to prove its AI strategy is delivering real financial growth.

The San Diego-based credit union is partnering with the AI lending giant to expand loan access, signaling a major shift in how local finance competes.

Navan CEO Ariel Cohen will pitch his growth strategy at the Needham conference, a key test for the travel tech firm amid stock declines and high hopes.